Purpose: This study aimed to evaluate choroidal thickness modifications before and after vitrectomy with or without phacoemulsification for idiopathic epiretinal membrane in the operated eye and in the unaffected fellow eye. Methods: In total, 53 eyes of 53 patients underwent 25-gauge pars plana vitrectomy plus internal limiting membrane peeling and air tamponade. Twenty-seven eyes underwent combined surgery with phacoemulsification and intraocular lens implantation. Choroidal thickness was measured using enhanced deep image spectral-domain optical coherence tomography at the fovea and at 500 and 2,500 µm from the fovea. Fellow eyes without any previous ocular surgery history served as controls. Results: Baseline comparison did not show significant differences between study and fellow eyes (p > 0.05). Choroidal thickness significantly decreased in the subfoveal area (p = 0.004) as well as at 500 µm (p = 0.026) and 2,500 µm nasally (p = 0.019) and at 500 µm (p = 0.039) and 2,500 µm (p = 0.005) temporally to the fovea. No significant changes were observed postoperatively in the superior and inferior areas (p > 0.05). No differences were found between eyes which underwent combined surgery and those which underwent vitrectomy alone (p > 0.05). The unaffected eyes did not show any significant changes (p > 0.05). Conclusions: Comparison of baseline values did not show any differences between affected and unaffected eyes, meaning that choroidal thickness was not influenced by the development of epiretinal membrane. Vitrectomy plus epiretinal and inner limiting membrane removal may influence choroidal homeostasis, leading to a decrease in choroidal thickness in the subfoveal, nasal, and temporal areas. Combined surgery did not show significant differences when compared to vitrectomy alone.

Keywords:
Choroidal thickness, Idiopathic epiretinal membrane, 25-Gauge vitrectomy
1.
Parver LM, Auker C, Carpenter DO: Choroidal blood flow as a heat dissipating mechanism in the macula. Am J Ophthalmol 1980;89:641-646.
2.
Spaide RF, Koizumi H, Pozzoni MC: Enhanced depth imaging spectral-domain optical coherence tomography. Am J Ophthalmol 2008;146:496-500.
3.
Wang J, Gao X, Huang W, et al: Swept-source optical coherence tomography imaging of macular retinal and choroidal structures in healthy eyes. BMC Ophthalmology 2015;15:122.
4.
Imamura Y, Fujiwara T, Margolis R, Spaide RF: Enhanced depth imaging optical coherence tomography of the choroid in central serous chorioretinopathy. Retina 2009;29:1469-1473.
5.
Maruko I, Iida T, Sugano Y, Oyamada H, Sekiryu T, Fujiwara T, Spaide RF: Subfoveal choroidal thickness after treatment of Vogt-Koyanagi-Harada disease. Retina 2011;31:510-517.
6.
Fujiwara T, Imamura Y, Margolis R, Slakter JS, Spaide RF: Enhanced depth imaging optical coherence tomography of the choroid in highly myopic eyes. Am J Ophthalmol 2009;148:445-450.
7.
Manjunath V, Goren J, Fujimoto JG, Duker JS: Analysis of choroidal thickness in age-related macular degeneration using spectral-domain optical coherence tomography. Am J Ophthalmol 2011;152:663-668.
8.
Chung SE, Kang SW, Lee JH, Kim YT: Choroidal thickness in polypoidal choroidal vasculopathy and exudative age-related macular degeneration. Ophthalmology 2011;118:840-845.
9.
Zeng J, Li J, Liu R, et al: Choroidal thickness in both eyes of patients with unilateral idiopathic macular hole. Ophthalmology 2012;119:2328-2333.
10.
Zhao F, Gandorfer A, Haritoglou C, et al: Epiretinal cell proliferation in macular pucker and vitreomacular traction syndrome: analysis of flat-mounted internal limiting membrane specimens. Retina 2013;33:77-88.
11.
Guidry C, Bradley KM, King JL: Tractional force generation by human Muller cells: growth factor responsiveness and integrin receptor involvement. Invest Ophthalmol Vis Sci 2003;44:1355-1363.
12.
Khono RI, Hata Y, Kawahara S, et al: Possible contribution of hyalocytes to idiopathic epiretinal membrane formation and its contraction. Br J Ophthalmol 2009;93:1020-1026.
13.
Parapuram SK, Chang B, Li L, et al: Differential effects of TGFβ and vitreous on the transformation of retinal pigment epithelial cells. Invest Ophthalmol Vis Sci 2009;50:5965-5974.
14.
Sebag J, Gupta P, Rosen RR, Garcia P, Sadun AA: Macular holes and macular pucker: the role of vitreoschisis as imaged by optical coherence tomography/scanning laser ophthalmoscopy. Trans Am Ophthalmol Soc 2007;105:121-129.
15.
Glenn JV, Stitt AW: The role of advanced glycation end products in retinal ageing and disease. Biochim Biophys Acta 2009;1790:1109-1116.
16.
Tezel G, Luo C, Yang X: Accelerated aging in glaucoma: immunohistochemical assessment of advanced glycation end products in the human retina and optic nerve head. Invest Ophthalmol Vis Sci 2007;48:1201-1211.
17.
Sebag J: Anomalous posterior vitreous detachment: a unifying concept in vitreo-retinal disease. Graefes Arch Clin Exp Ophthalmol 2004;242:690-698.
18.
Michalewska Z, Michalewski J, Adelman RA, Zawislak E, Nawrocki J: Choroidal thickness measured with swept source optical coherence tomography before and after vitrectomy with internal limiting membrane peeling for idiopathic epiretinal membranes. Retina 2015;35:487-491.
19.
Michalewska Z, Michalewski J, Ornafel-Sagan K, Nawrocki J: Swept-source optical coherence tomography correlations between retina and choroid before and after vitrectomy for epiretinal membranes. Am J Ophthalmol 2016;165:100-107.
20.
Kang EC, Lee KO, Koh HJ: Changes in choroidal thickness after vitrectomy for epiretinal membrane combined with vitreomacular traction. Acta Ophthalmol 2016, DOI: 10.1111/aos.13097.
21.
Ahn SJ, Woo SJ, Park KH: Choroidal thickness change following vitrectomy in idiopathic epiretinal membrane and macular hole. Graefes Arch Clin Exp Ophthalmol 2016;254:1059-1067.
22.
Hwang JU, Sohn J, Moon BG, et al: Assessment of macular function for idiopathic epiretinal membranes classified by spectral-domain optical coherence tomography. Invest Ophthalmol Vis Sci 2012;53:3562-3569.
23.
Ferris FL III, Kassof A, Brsnick GH, et al: New visual acuity charts for clinical research. Am J Ophthalmol 1982;94:91-96.
24.
Manjunath V, Taha M, Fujimoto JG, Duker JS: Choroidal thickness in normal eyes measured using Cirrus HD optical coherence tomography. Am J Ophthalmol 2010;150:325-329.e321.
25.
Rahman V, Chen FK, Yeoh J, Patel P, Tufail A, Da Cruz L: Repeatability of manual subfoveal choroidal thickness measurements in healthy subjects using the technique of enhanced depth imaging optical coherence tomography. Invest Ophthalmol Vis Sci 2011;52:2267-2271.
26.
Wei WB, Xu L, Jonas JB, et al: Subfoveal choroidal thickness: the Beijing Eye Study. Ophthalmology 2013;120:175-180.
27.
Margolis R, Spaide RF: A pilot study of enhanced depth imaging optical coherence tomography of the choroid in normal eyes. Am J Ophthalmol 2009;147:811-815.
28.
Ikuno Y, Kawaguchi K, Nouchi T, Yasuno Y: Choroidal thickness in healthy Japanese subjects. Invest Ophthalmol Vis Sci 2010;51:2173-2176.
29.
Ding X, Li J, Zeng J, et al: Choroidal thickness in healthy Chinese subjects. Invest Ophthalmol Vis Sci 2011;52:9555-9560.
30.
Ouyang Y, Heussen FM, Mokwa N, et al: Spatial distribution of posterior pole choroidal thickness by spectral domain optical coherence tomography. Invest Ophthalmol Vis Sci 2011;52:7019-7026.
31.
Kadonosono K, Itoh N, Nomura E, Ohno S: Perifoveal microcirculation in eyes with epiretinal membranes. Br J Ophthalmol 1999;83:1329-1331.
32.
Holekamp NM, Shui YB, Beebe DC: Vitrectomy surgery increases oxygen exposure to the lens: a possible mechanism for nuclear cataract formation. Am J Ophthalmol 2005;139:302-310.
33.
Yu DY, Cringle SJ: Retinal degeneration and local oxygen metabolism. Exp Eye Res 2005;80:745-751.
34.
Friberg TR, Lace JW: A comparison of the elastic properties of human choroid and sclera. Exp Eye Res 1988;47:429-436.
35.
Pierru A, Carles M, Gastaud P, Baillif S: Measurement of subfoveal choroidal thickness after cataract surgery in enhanced depth imaging optical coherence tomography. Invest Ophthalmol Vis Sci 2014;22;55:4967-4974.
36.
Noda Y, Ogawa A, Toyama T, Ueta T: Long-term increase in subfoveal choroidal thickness after surgery for senile cataracts. Am J Ophthalmol 2014;158:455-459.
37.
Ohsugi H, Ikuno Y, Ohara Z, et al: Changes in choroidal thickness after cataract surgery. J Cataract Refract Surg 2014;40:184-191.
38.
Jones J, Francis P: Ophthalmic utility of topical bromfenac, a twice-daily nonsteroidal anti-inflammatory agent. Expert Opin Pharmacother 2009;10:2379-2385.
39.
Xu H, Chen M, Forrester JV, Lois N: Cataract surgery induces retinal pro-inflammatory gene expression and protein secretion. Invest Ophthalmol Vis Sci 2011;52:249-255.
40.
Nakayama M, Keino H, Okada AA, et al: Enhanced depth imaging optical coherence tomography of the choroid in Vogt-Koyanagi-Harada disease. Retina 2012;32:2061-2069.
41.
Aoyagi R, Hayashi T, Masai A, et al: Subfoveal choroidal thickness in multiple evanescent white dot syndrome. Clin Exp Optom 2012;95:212-217.
42.
Shao L, Xu L, Chen CX, et al: Reproducibility of subfoveal choroidal thickness measurements with enhanced depth imaging by spectral-domain optical coherence tomography. Invest Ophthalmol Vis Sci 2013;54:230-233.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.